Immunochemotherapy with Alemtuzumab and FC in High-Risk CLL


Immunochemotherapy with Alemtuzumab and FC in High-Risk CLL
Slides from a presentation at ASH 2011 and transcribed comments from a recent interview with John P Leonard, MD (4/6/12)

Geisler CH et al. Immunochemotherapy with low-dose subcutaneous alemtuzumab (A) plus oral fludarabine and cyclophosphamide (FC) is safe and induces more and deeper complete remissions in untreated patients with high-risk chronic lymphocytic leukemia (CLL) than chemotherapy with FC alone. An early analysis of the randomized Phase-III HOVON68 CLL trial. Proc ASH 2011;Abstract 290.

Dr Leonard is Richard T Silver Distinguished Professor of Hematology and Medical Oncology and Professor of Medicine at Weill Cornell Medical College in New York, New York.